Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib

Authors

  • Liang Joo Leow Aesthetic Dermatology, 69 Burton Street, Darlinghurst NSW 2010, Sydney, Australia; epartment of Dermatology, St Vincent’s Private Hospital, Sydney, Australia
  • Vicki Howard School of Medicine, University of Notre Dame Australia, Sydney, Australia

DOI:

https://doi.org/10.2340/actadv.v102.2740

Keywords:

Basal cell carcinoma, sonidegib, Hedgehog pathway inhibitor, locally advanced BCC

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015; 88: 167-179.

Ciążyńska M, Kamińska-Winciorek G, Lange D, Lewandowski B, Reich A, Sławińska M, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep 2021; 11: 4337.

https://doi.org/10.1038/s41598-021-83502-8

Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer 2014; 111: 1476-1481.

https://doi.org/10.1038/bjc.2014.270

Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol 2020; 182: 1369-1378.

https://doi.org/10.1111/bjd.18552

Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol 2018; 32: 372-381.

https://doi.org/10.1111/jdv.14542

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol 2015; 16: 716-728.

https://doi.org/10.1016/S1470-2045(15)70100-2

Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016; 75: 113-125.e115.

https://doi.org/10.1016/j.jaad.2016.02.1226

No authors listed. Sonidegib for basal cell carcinoma. Aust Prescr 2018; 41: 94.

https://doi.org/10.18773/austprescr.2018.025

Elder D, Massi D, Scolyer R, Willemze R. WHO classification of skin tumors. Lyon: International Agency for Research on Cancer, World Health Organization, International Academy of Pathology; 2018: p. 470.

Dummer R, Lear JT, Guminski A, Leow LJ, Squittieri N, Migden M. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months. J Am Acad Dermatol 2021; 84: 1162-1164.

https://doi.org/10.1016/j.jaad.2020.08.042

Migden MR, Chang ALS, Dirix L, Stratigos AJ, Lear JT. Emerging trends in the treatment of advanced basal cell carcinoma. Cancer Treat Rev 2018; 64: 1-10.

https://doi.org/10.1016/j.ctrv.2017.12.009

Gutzmer R, Robert C, Loquai C, Schadendorf D, Squittieri N, Arntz R, et al. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. BMC Cancer 2021; 21: 1244.

https://doi.org/10.1186/s12885-021-08968-1

Leow LJ, Teh N. Clinical clearance of complex basal cell carcinoma in patients receiving sonidegib: a case series. Dermatol Ther 2022; 35: e15217.

https://doi.org/10.1111/dth.15217

Lewis K, Dummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of sonidegib following dose reduction and treatment interruption in patients with advanced basal cell carcinoma during 42-month BOLT trial. Dermatol Ther (Heidelb) 2021; 11: 2225-2234.

https://doi.org/10.1007/s13555-021-00619-4

Teh N, Leow LJ. The role of actin in muscle spasms in a case series of patients with advanced basal cell carcinoma treated with a hedgehog pathway inhibitor. Dermatol Ther (Heidelb) 2021; 11: 293-299.

https://doi.org/10.1007/s13555-020-00464-x

Downloads

Published

2022-11-07

How to Cite

Leow, L. J., & Howard, V. (2022). Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib. Acta Dermato-Venereologica, 102, adv00809. https://doi.org/10.2340/actadv.v102.2740

Issue

Section

Short Communication

Categories